DV
Dividend Vision

CAPR — Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. (CAPR)

Total return is 30.4% over the past 24.2 years, 1062.3 points behind SPY at 1092.7%. Its deepest 1-year drawdown was 89.1%.

Capricor Therapeutics is a clinical-stage biotechnology company developing cell and exosome-based therapeutics to treat Duchenne muscular dystrophy and other diseases with unmet medical needs, with its lead candidate Deramiocel currently in phase 3 clinical trials. The company does not currently distribute dividends. Capricor appeals to investors seeking exposure to early-stage biotech innovation rather than current income.

CAPR key facts

Asset type
Stock
Asset class
Equity
Inception date
06/20/2002
Last close
$6.65
Market cap
$386,424,768
Average volume
65982900.0
Payment date
06/05/2019
Beta
0.528
Payout ratio
0.0
Forward P/E
78.7402
EPS
$-2.45